May 21, 2025 - 03:01

In a significant development for the medical technology sector, a leading global provider has received certification from Health Canada for its IgniteRF platform, which incorporates the cutting-edge QuantumRF technology. This advancement underscores the company's commitment to delivering innovative solutions that enhance patient care and treatment outcomes.
The IgniteRF platform is designed to offer a range of non-invasive aesthetic procedures, utilizing radiofrequency technology to improve skin tone and texture while promoting collagen production. The introduction of QuantumRF technology enhances the platform's capabilities, allowing for more precise and effective treatments.
With this certification, healthcare professionals in Canada can now access state-of-the-art tools that facilitate improved patient experiences and results. The approval marks a pivotal moment for the company, as it expands its footprint in the Canadian market and reaffirms its dedication to pioneering advancements in medical aesthetics. This development is expected to drive further growth and innovation in the field, benefiting both practitioners and patients alike.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...